Option chain shows key data for UCB's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for UCB.

UCB (OTC:UCBJY) Stock, Option Chain

UCB ADR

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Biogen - logo

Analyst Color

Biotech

Equities

News

Health Care

Reiteration

Analyst Ratings

Trading Ideas

General

BIIB

UCBJF

UCBJY

UCB and Biogen&#39;s Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

FDA Class I Recall

FDA Approves UCB&#39;s Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

Large Cap

UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48 weeks.

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

UCB SA

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company...

Barclays Remains a Buy on UCB SA (0NZT)

Deutsche Bank raised the firm's price target on UCB (UCBJF) to EUR 215 from EUR 200 and keeps a Buy rating on the shares. Published first on TheFly...

UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of €17...

UCB SA (0NZT) Receives a Buy from Barclays

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

UCB gets FDA approval for Bimzelx for hidradenitis suppurativa

JPMorgan analyst Richard Vosser raised the firm's price target on UCB (UCBJF) to EUR 230 from EUR 200 and keeps an Overweight rating on the shares....

UCB price target raised to EUR 230 from EUR 200 at JPMorgan

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of €24...

ClearBridge International Growth EAFE Strategy Q4 2024 Commentary

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) yesterday and set a price target of €240.00. The com...

ARGNF

ARGX

ASML

ASMLF

AZNCF

CHKP

EDPFY

ELCPF

ESLOF

ESLOY

HESAF

HESAY

HXGBF

HXGBY

IDEXF

IDEXY

LDNXF

LNSTY

MAKSF

MAKSY

MBFJF

MLTX

MUFG

NONOF

NPXYY

SAPGF

SHOP

SLRN

SNEJF

SONY

SPOT

TSMWF

TYNPF

Press Releases

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

Comments

UCB

UCB (UCBJY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga